Six lung adenocarcinoma cell lines, with KRAS, EGFR, or ALK driver mutations were evaluated for Debio 1143 dose-dependent growth inhibition to identify optimal concentrations for use in combination assays (Table 1). The gene discussed is KRAS; the disease is lung adenocarcinoma.